JP2015527399A - 置換−１，４−ジヒドロピラゾロ［４，３−ｂ］インドール - Google Patents
置換−１，４−ジヒドロピラゾロ［４，３−ｂ］インドール Download PDFInfo
- Publication number
- JP2015527399A JP2015527399A JP2015531237A JP2015531237A JP2015527399A JP 2015527399 A JP2015527399 A JP 2015527399A JP 2015531237 A JP2015531237 A JP 2015531237A JP 2015531237 A JP2015531237 A JP 2015531237A JP 2015527399 A JP2015527399 A JP 2015527399A
- Authority
- JP
- Japan
- Prior art keywords
- fluoropyrazolo
- indole
- indol
- methyl
- dihydropyrazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PJHRBUCIVIJVKT-UHFFFAOYSA-N 1,4-dihydropyrazolo[4,3-b]indole Chemical class N1C2=CC=CC=C2C2=C1C=NN2 PJHRBUCIVIJVKT-UHFFFAOYSA-N 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 427
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 41
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 16
- 235000020824 obesity Nutrition 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 12
- -1 thiopheneyl Chemical group 0.000 claims description 471
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 71
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 125000005843 halogen group Chemical group 0.000 claims description 59
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- 239000001257 hydrogen Substances 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- 125000001153 fluoro group Chemical group F* 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000005955 1H-indazolyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 8
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 7
- 206010022489 Insulin Resistance Diseases 0.000 claims description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 7
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 208000011661 metabolic syndrome X Diseases 0.000 claims description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 7
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 6
- 206010033307 Overweight Diseases 0.000 claims description 6
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 229960002965 pravastatin Drugs 0.000 claims description 6
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 6
- 125000005899 2,3-dihydro-1H-pyrrolo[2,3-b]pyridinyl group Chemical group 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 5
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- BXLCENGNDVFRAZ-UHFFFAOYSA-N 3-hydroxyazetidine-1-carbaldehyde Chemical compound OC1CN(C=O)C1 BXLCENGNDVFRAZ-UHFFFAOYSA-N 0.000 claims description 4
- TZDONXAHPXKEGZ-UHFFFAOYSA-N 6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-1-(2-hydroxyethyl)-5-methyl-3h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N(CCO)C(=O)N2)=C2N=C1C TZDONXAHPXKEGZ-UHFFFAOYSA-N 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- VVQSCGIRSJAVKW-QAMHXRKUSA-N (1r,2s,5s)-3-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CN=C(N2[C@@H]([C@@H]3C[C@@H]3C2)C(N)=O)N=C1C VVQSCGIRSJAVKW-QAMHXRKUSA-N 0.000 claims description 3
- KKFJVSMJOYXFQJ-LBPRGKRZSA-N (3s)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]pyrrolidin-3-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@H](O)C1 KKFJVSMJOYXFQJ-LBPRGKRZSA-N 0.000 claims description 3
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 3
- 125000005960 1,4-diazepanyl group Chemical group 0.000 claims description 3
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 3
- HKDFRDIIELOLTJ-UHFFFAOYSA-N 1,4-dithianyl Chemical group [CH]1CSCCS1 HKDFRDIIELOLTJ-UHFFFAOYSA-N 0.000 claims description 3
- BHJMIMMYHSMRMK-UHFFFAOYSA-N 4-benzyl-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1CC1=CC=CC=C1 BHJMIMMYHSMRMK-UHFFFAOYSA-N 0.000 claims description 3
- NWAFZOQKWYFAND-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-hydroxyethyl)-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCCO)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 NWAFZOQKWYFAND-UHFFFAOYSA-N 0.000 claims description 3
- AMUJWJIEEPBMJN-UHFFFAOYSA-N 6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(NC(=O)N2)=C2N=C1C AMUJWJIEEPBMJN-UHFFFAOYSA-N 0.000 claims description 3
- ZXAPVSLYIINGLH-UHFFFAOYSA-N 6-chloro-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC=C(Cl)C=C2N1C1=CC(NC=N2)=C2N=C1C ZXAPVSLYIINGLH-UHFFFAOYSA-N 0.000 claims description 3
- BGVWCIRYUNODHW-UHFFFAOYSA-N 7-fluoro-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(NC=N2)=C2N=C1C BGVWCIRYUNODHW-UHFFFAOYSA-N 0.000 claims description 3
- UCYIXXMYPVYCPX-UHFFFAOYSA-N 7-fluoro-4-[2-methyl-6-(2-methylsulfonylethyl)pyridin-3-yl]-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC(CCS(C)(=O)=O)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 UCYIXXMYPVYCPX-UHFFFAOYSA-N 0.000 claims description 3
- BPCCTTNRJCTGHS-UHFFFAOYSA-N 7-fluoro-4-pyridin-3-yl-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC=CN=C1 BPCCTTNRJCTGHS-UHFFFAOYSA-N 0.000 claims description 3
- FKROPYPGXGWRCM-UHFFFAOYSA-N [4-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-1-methylpyrazol-3-yl]methanol Chemical compound OCC1=NN(C)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 FKROPYPGXGWRCM-UHFFFAOYSA-N 0.000 claims description 3
- VMOTYFACJUDBEV-UHFFFAOYSA-N [4-[(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)methyl]phenyl]-morpholin-4-ylmethanone Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1CC(C=C1)=CC=C1C(=O)N1CCOCC1 VMOTYFACJUDBEV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003725 azepanyl group Chemical group 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000004069 aziridinyl group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003551 oxepanyl group Chemical group 0.000 claims description 3
- 125000003566 oxetanyl group Chemical group 0.000 claims description 3
- 125000000466 oxiranyl group Chemical group 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 201000002859 sleep apnea Diseases 0.000 claims description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 3
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 3
- 125000001583 thiepanyl group Chemical group 0.000 claims description 3
- 125000002053 thietanyl group Chemical group 0.000 claims description 3
- VVQSCGIRSJAVKW-AJLCLMPTSA-N (1r,2r,5s)-3-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CN=C(N2[C@H]([C@@H]3C[C@@H]3C2)C(N)=O)N=C1C VVQSCGIRSJAVKW-AJLCLMPTSA-N 0.000 claims description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 2
- JVXZMZFHASCFTM-SECBINFHSA-N (2r)-1-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]propan-2-ol Chemical compound CC1=NC(NC[C@H](O)C)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 JVXZMZFHASCFTM-SECBINFHSA-N 0.000 claims description 2
- RNDRRILNXQNKKZ-SNVBAGLBSA-N (2r)-1-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]amino]propan-2-ol Chemical compound CC1=NC(NC[C@H](O)C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 RNDRRILNXQNKKZ-SNVBAGLBSA-N 0.000 claims description 2
- MYNYHVTZJXRKKZ-GFCCVEGCSA-N (2r)-3-[6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methylimidazo[4,5-b]pyridin-3-yl]propane-1,2-diol Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N=CN2C[C@@H](O)CO)=C2N=C1C MYNYHVTZJXRKKZ-GFCCVEGCSA-N 0.000 claims description 2
- LKJUSTPUAXMOMO-LLVKDONJSA-N (2r)-3-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]propane-1,2-diol Chemical compound CC1=NC(NC[C@@H](O)CO)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 LKJUSTPUAXMOMO-LLVKDONJSA-N 0.000 claims description 2
- JVXZMZFHASCFTM-VIFPVBQESA-N (2s)-1-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]propan-2-ol Chemical compound CC1=NC(NC[C@@H](O)C)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 JVXZMZFHASCFTM-VIFPVBQESA-N 0.000 claims description 2
- XFLZIIASAHFMPT-VIFPVBQESA-N (2s)-2-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]propan-1-ol Chemical compound CC1=NC(N[C@H](CO)C)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 XFLZIIASAHFMPT-VIFPVBQESA-N 0.000 claims description 2
- MYNYHVTZJXRKKZ-LBPRGKRZSA-N (2s)-3-[6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methylimidazo[4,5-b]pyridin-3-yl]propane-1,2-diol Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N=CN2C[C@H](O)CO)=C2N=C1C MYNYHVTZJXRKKZ-LBPRGKRZSA-N 0.000 claims description 2
- GFMMMVIGRGRSEL-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-yl]methanone Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=CC=1C(=O)N1CC(N)C1 GFMMMVIGRGRSEL-UHFFFAOYSA-N 0.000 claims description 2
- CTBMTGKGHSVVLR-UHFFFAOYSA-N (3-aminoazetidin-1-yl)-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]methanone Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1C(=O)N1CC(N)C1 CTBMTGKGHSVVLR-UHFFFAOYSA-N 0.000 claims description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 2
- ZRTDJGCQJYSPSV-CYBMUJFWSA-N (3r)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperidin-3-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC[C@@H](O)C1 ZRTDJGCQJYSPSV-CYBMUJFWSA-N 0.000 claims description 2
- KKFJVSMJOYXFQJ-GFCCVEGCSA-N (3r)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]pyrrolidin-3-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@@H](O)C1 KKFJVSMJOYXFQJ-GFCCVEGCSA-N 0.000 claims description 2
- BVWYKVYJKDAOHM-CYBMUJFWSA-N (3r)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]pyrrolidin-3-ol Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@@H](O)C1 BVWYKVYJKDAOHM-CYBMUJFWSA-N 0.000 claims description 2
- ZPZQUANGRXUVAS-HZPDHXFCSA-N (3r,4r)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]pyrrolidine-3,4-diol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1C[C@@H](O)[C@H](O)C1 ZPZQUANGRXUVAS-HZPDHXFCSA-N 0.000 claims description 2
- ZRTDJGCQJYSPSV-ZDUSSCGKSA-N (3s)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperidin-3-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC[C@H](O)C1 ZRTDJGCQJYSPSV-ZDUSSCGKSA-N 0.000 claims description 2
- BVWYKVYJKDAOHM-ZDUSSCGKSA-N (3s)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]pyrrolidin-3-ol Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@H](O)C1 BVWYKVYJKDAOHM-ZDUSSCGKSA-N 0.000 claims description 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims description 2
- JAIZHQLBZUGIQV-UHFFFAOYSA-N 1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]azetidin-3-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC(O)C1 JAIZHQLBZUGIQV-UHFFFAOYSA-N 0.000 claims description 2
- CDKNKEYEZIFKOB-UHFFFAOYSA-N 1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperidine-4-carbonitrile Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC(C#N)CC1 CDKNKEYEZIFKOB-UHFFFAOYSA-N 0.000 claims description 2
- KKYCXXHACYYMAT-UHFFFAOYSA-N 1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridine-2-carbonyl]azetidine-3-carbonitrile Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1C(=O)N1CC(C#N)C1 KKYCXXHACYYMAT-UHFFFAOYSA-N 0.000 claims description 2
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims description 2
- JUQPWBIRVPOLPW-UHFFFAOYSA-N 2-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-yl]-methylamino]ethanol Chemical compound C1=NC(N(CCO)C)=CC(C)=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 JUQPWBIRVPOLPW-UHFFFAOYSA-N 0.000 claims description 2
- HRQSQNPDQBTKRC-UHFFFAOYSA-N 2-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]ethanol Chemical compound CC1=NC(NCCO)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 HRQSQNPDQBTKRC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 2
- NTFZDFZVGNCXQP-UHFFFAOYSA-N 3-[6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methylimidazo[4,5-b]pyridin-3-yl]propan-1-ol Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N=CN2CCCO)=C2N=C1C NTFZDFZVGNCXQP-UHFFFAOYSA-N 0.000 claims description 2
- PSXVTQZWNCZZEK-UHFFFAOYSA-N 4-(1,4-dimethylindazol-5-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)C(C=NN2C)=C2C=C1 PSXVTQZWNCZZEK-UHFFFAOYSA-N 0.000 claims description 2
- OGFYDTCSKYEYQW-UHFFFAOYSA-N 4-(1,5-dimethylindazol-6-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N(C)N=C2)=C2C=C1C OGFYDTCSKYEYQW-UHFFFAOYSA-N 0.000 claims description 2
- FSDBXNSGEOIMLV-UHFFFAOYSA-N 4-(1-ethyl-3,5-dimethylpyrazol-4-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound CCN1N=C(C)C(N2C3=CC=C(F)C=C3C=3NN=CC=32)=C1C FSDBXNSGEOIMLV-UHFFFAOYSA-N 0.000 claims description 2
- KUOHQQCPDGBENS-UHFFFAOYSA-N 4-(2,5-dimethylindazol-6-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC2=NN(C)C=C2C=C1C KUOHQQCPDGBENS-UHFFFAOYSA-N 0.000 claims description 2
- MVLJEXMTANOCNN-UHFFFAOYSA-N 4-(2,6-dimethylindazol-5-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC2=CN(C)N=C2C=C1C MVLJEXMTANOCNN-UHFFFAOYSA-N 0.000 claims description 2
- SLJDDLKTPNNCBT-UHFFFAOYSA-N 4-(2,6-dimethylpyridin-3-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC(C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 SLJDDLKTPNNCBT-UHFFFAOYSA-N 0.000 claims description 2
- IUZBXISRROMZSL-UHFFFAOYSA-N 4-(3,5-dimethylimidazo[4,5-b]pyridin-6-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N=CN2C)=C2N=C1C IUZBXISRROMZSL-UHFFFAOYSA-N 0.000 claims description 2
- MKXDGJICFKWFKG-UHFFFAOYSA-N 4-(3-ethyl-5-methylimidazo[4,5-b]pyridin-6-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)N=C2N(CC)C=NC2=C1 MKXDGJICFKWFKG-UHFFFAOYSA-N 0.000 claims description 2
- LYDNIWUUAXKIEE-UHFFFAOYSA-N 4-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-1h-pyrazole-5-carbonitrile Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C=1C=NNC=1C#N LYDNIWUUAXKIEE-UHFFFAOYSA-N 0.000 claims description 2
- OTERKSQZXOAQLU-UHFFFAOYSA-N 4-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-hydroxyethyl)-3-methylbenzamide Chemical compound CC1=CC(C(=O)NCCO)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 OTERKSQZXOAQLU-UHFFFAOYSA-N 0.000 claims description 2
- RKBBSKVVMWTWSP-UHFFFAOYSA-N 4-[2-(3,3-difluoroazetidin-1-yl)-4-methylpyrimidin-5-yl]-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC(F)(F)C1 RKBBSKVVMWTWSP-UHFFFAOYSA-N 0.000 claims description 2
- MOXHTKRNDVXYQH-UHFFFAOYSA-N 4-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]-1-methylpiperazin-2-one Chemical compound C1C(=O)N(C)CCN1C1=NC=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=N1 MOXHTKRNDVXYQH-UHFFFAOYSA-N 0.000 claims description 2
- SUCKSZMUUYQFPE-UHFFFAOYSA-N 4-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperazin-2-one Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCNC(=O)C1 SUCKSZMUUYQFPE-UHFFFAOYSA-N 0.000 claims description 2
- YRZJHIFXPFONPA-UHFFFAOYSA-N 4-benzyl-6,7-difluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C=2C=C(F)C(F)=CC=2N1CC1=CC=CC=C1 YRZJHIFXPFONPA-UHFFFAOYSA-N 0.000 claims description 2
- BZDZEPPVFCZALI-UHFFFAOYSA-N 5-(7-fluoro-1H-pyrazolo[4,3-b]indol-4-yl)-N-(2-methoxyethyl)-4-methylpyridine-2-carboxamide Chemical compound FC1=CC=2C3=C(N(C2C=C1)C=1C(=CC(=NC1)C(=O)NCCOC)C)C=NN3 BZDZEPPVFCZALI-UHFFFAOYSA-N 0.000 claims description 2
- UDYJXQLMLNNFKF-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(N)=O)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 UDYJXQLMLNNFKF-UHFFFAOYSA-N 0.000 claims description 2
- KUNLGEIDYTZFHY-SNVBAGLBSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-2-[(3r)-3-hydroxypyrrolidin-1-yl]-1h-pyrimidin-6-one Chemical compound C1[C@H](O)CCN1C(NC1=O)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 KUNLGEIDYTZFHY-SNVBAGLBSA-N 0.000 claims description 2
- PMOUPCPHWZIIDJ-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-3,4-dimethylpyridin-2-amine Chemical compound CC1=C(N)N=CC(N2C3=CC=C(F)C=C3C=3NN=CC=32)=C1C PMOUPCPHWZIIDJ-UHFFFAOYSA-N 0.000 claims description 2
- XILNQDGEMCTTDH-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 XILNQDGEMCTTDH-UHFFFAOYSA-N 0.000 claims description 2
- QRUUCMHHMXMVTP-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridine-2-carboxamide Chemical compound CC1=CC(C(N)=O)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 QRUUCMHHMXMVTP-UHFFFAOYSA-N 0.000 claims description 2
- AQJZFCBAFGBITJ-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 AQJZFCBAFGBITJ-UHFFFAOYSA-N 0.000 claims description 2
- GLRNWVJKGLNZFV-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methyl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(N2C3=CC=C(F)C=C3C=3NN=CC=32)=C1C GLRNWVJKGLNZFV-UHFFFAOYSA-N 0.000 claims description 2
- DTVNCJQGACMIIV-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-amine Chemical compound CC1=NC(N)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 DTVNCJQGACMIIV-UHFFFAOYSA-N 0.000 claims description 2
- ZYDAFXAZKNYBDP-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n,4-dimethylpyridin-2-amine Chemical compound C1=NC(NC)=CC(C)=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 ZYDAFXAZKNYBDP-UHFFFAOYSA-N 0.000 claims description 2
- ANAQPLOTTOOVNV-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n,4-dimethylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(C)=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 ANAQPLOTTOOVNV-UHFFFAOYSA-N 0.000 claims description 2
- UCQDYXZRRRKHKE-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n,6-dimethylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NC)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 UCQDYXZRRRKHKE-UHFFFAOYSA-N 0.000 claims description 2
- SRMRNJQSSJRSJJ-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n,n,4-trimethylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C)C)=CC(C)=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 SRMRNJQSSJRSJJ-UHFFFAOYSA-N 0.000 claims description 2
- WQRAFCYWQVQSLM-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-hydroxyethyl)-4-methylpyridine-2-carboxamide Chemical compound CC1=CC(C(=O)NCCO)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 WQRAFCYWQVQSLM-UHFFFAOYSA-N 0.000 claims description 2
- DFAQLUXZASRGNV-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-hydroxyethyl)-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NCCO)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 DFAQLUXZASRGNV-UHFFFAOYSA-N 0.000 claims description 2
- QTWVXUXAXIDIQJ-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-hydroxyethyl)-n,6-dimethylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)N(CCO)C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 QTWVXUXAXIDIQJ-UHFFFAOYSA-N 0.000 claims description 2
- DYTNRLKNPPUCBN-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(2-methoxyethyl)-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NCCOC)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 DYTNRLKNPPUCBN-UHFFFAOYSA-N 0.000 claims description 2
- KYMSFGAJAKNKQD-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(3-hydroxypropyl)-4-methylpyridine-2-carboxamide Chemical compound CC1=CC(C(=O)NCCCO)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 KYMSFGAJAKNKQD-UHFFFAOYSA-N 0.000 claims description 2
- ZAZZGEDRNDDMIR-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-(3-hydroxypropyl)-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NCCCO)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 ZAZZGEDRNDDMIR-UHFFFAOYSA-N 0.000 claims description 2
- BWLPPOWVJQVABE-SNVBAGLBSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-[(2r)-2-hydroxypropyl]-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NC[C@H](O)C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 BWLPPOWVJQVABE-SNVBAGLBSA-N 0.000 claims description 2
- BWLPPOWVJQVABE-JTQLQIEISA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-[(2s)-2-hydroxypropyl]-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NC[C@@H](O)C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 BWLPPOWVJQVABE-JTQLQIEISA-N 0.000 claims description 2
- SDYJEGXRICWVMB-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-[1-(hydroxymethyl)cyclopropyl]-4-methylpyridine-2-carboxamide Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=CC=1C(=O)NC1(CO)CC1 SDYJEGXRICWVMB-UHFFFAOYSA-N 0.000 claims description 2
- MBTTVIVBRSZLPG-UHFFFAOYSA-N 5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n-[1-(hydroxymethyl)cyclopropyl]-6-methylpyridine-2-carboxamide Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1C(=O)NC1(CO)CC1 MBTTVIVBRSZLPG-UHFFFAOYSA-N 0.000 claims description 2
- LWQQOBXTPSOJDL-UHFFFAOYSA-N 6,7-difluoro-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=C(F)C=C2N1C1=CC(NC=N2)=C2N=C1C LWQQOBXTPSOJDL-UHFFFAOYSA-N 0.000 claims description 2
- PEWYGTLRHLRPDV-UHFFFAOYSA-N 6,7-difluoro-4-pyridin-3-yl-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C=2C=C(F)C(F)=CC=2N1C1=CC=CN=C1 PEWYGTLRHLRPDV-UHFFFAOYSA-N 0.000 claims description 2
- ZGXYSNNZLZWSDJ-UHFFFAOYSA-N 6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-3-(3-hydroxypropyl)-5-methyl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(NC(=O)N2CCCO)=C2N=C1C ZGXYSNNZLZWSDJ-UHFFFAOYSA-N 0.000 claims description 2
- MLTRKWNLWDDKEU-UHFFFAOYSA-N 6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-7-methyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)C(NC(=O)N2)=C2N=C1 MLTRKWNLWDDKEU-UHFFFAOYSA-N 0.000 claims description 2
- IPEFGMPMIDTJEW-UHFFFAOYSA-N 6-amino-5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)pyridine-3-carboxylic acid Chemical compound NC1=NC=C(C(O)=O)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 IPEFGMPMIDTJEW-UHFFFAOYSA-N 0.000 claims description 2
- BIIWWXKROBCNQB-UHFFFAOYSA-N 6-chloro-7-fluoro-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=C(Cl)C=C2N1C1=CC(NC=N2)=C2N=C1C BIIWWXKROBCNQB-UHFFFAOYSA-N 0.000 claims description 2
- PKHRLYLVTPAMDQ-UHFFFAOYSA-N 7-fluoro-4-(1,3,5-trimethylpyrazol-4-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NN(C)C(C)=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 PKHRLYLVTPAMDQ-UHFFFAOYSA-N 0.000 claims description 2
- XMQKDYKZIPIZBO-UHFFFAOYSA-N 7-fluoro-4-(1-phenylethyl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C(C)C1=CC=CC=C1 XMQKDYKZIPIZBO-UHFFFAOYSA-N 0.000 claims description 2
- WQSXXYVWURXQHK-UHFFFAOYSA-N 7-fluoro-4-(2-methyl-6-piperazin-1-ylpyridin-3-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCNCC1 WQSXXYVWURXQHK-UHFFFAOYSA-N 0.000 claims description 2
- CQPVFNFMSYBFNM-UHFFFAOYSA-N 7-fluoro-4-(2-methylpyrazol-3-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CN1N=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 CQPVFNFMSYBFNM-UHFFFAOYSA-N 0.000 claims description 2
- ANPBEMFSBAZYTH-UHFFFAOYSA-N 7-fluoro-4-(2-methylpyridin-3-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 ANPBEMFSBAZYTH-UHFFFAOYSA-N 0.000 claims description 2
- YRZSLWOEBGOYCT-UHFFFAOYSA-N 7-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=NN2CCNCC2=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 YRZSLWOEBGOYCT-UHFFFAOYSA-N 0.000 claims description 2
- GKLASFPXAFLKOS-UHFFFAOYSA-N 7-fluoro-4-(4-methyl-1h-indazol-5-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)C(C=NN2)=C2C=C1 GKLASFPXAFLKOS-UHFFFAOYSA-N 0.000 claims description 2
- BGZYUWQQATZBHE-UHFFFAOYSA-N 7-fluoro-4-(4-methylpyrimidin-5-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 BGZYUWQQATZBHE-UHFFFAOYSA-N 0.000 claims description 2
- BAHHORPTLRLLTM-UHFFFAOYSA-N 7-fluoro-4-(5-methyl-1h-indazol-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(NN=C2)=C2C=C1C BAHHORPTLRLLTM-UHFFFAOYSA-N 0.000 claims description 2
- RNWCXVSCZJOBKL-UHFFFAOYSA-N 7-fluoro-4-(5-methyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)N2N=CN=C2C=C1 RNWCXVSCZJOBKL-UHFFFAOYSA-N 0.000 claims description 2
- GPAMAFNHQLQOTA-UHFFFAOYSA-N 7-fluoro-4-(6-methoxy-2-methylpyridin-3-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC(OC)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 GPAMAFNHQLQOTA-UHFFFAOYSA-N 0.000 claims description 2
- XXKLVEQACZAVIB-UHFFFAOYSA-N 7-fluoro-4-(6-methyl-1h-indazol-5-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(C=NN2)=C2C=C1C XXKLVEQACZAVIB-UHFFFAOYSA-N 0.000 claims description 2
- IYGXIFDOCWWMLQ-UHFFFAOYSA-N 7-fluoro-4-(6-methylpyridin-2-yl)-1h-pyrazolo[4,3-b]indole Chemical compound CC1=CC=CC(N2C3=CC=C(F)C=C3C=3NN=CC=32)=N1 IYGXIFDOCWWMLQ-UHFFFAOYSA-N 0.000 claims description 2
- RRCNPYRCOUOTDZ-UHFFFAOYSA-N 7-fluoro-4-(7-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)C(NC=N2)=C2N=C1 RRCNPYRCOUOTDZ-UHFFFAOYSA-N 0.000 claims description 2
- GZVOXNRYSRNICD-UHFFFAOYSA-N 7-fluoro-4-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-1h-pyrazolo[4,3-b]indole Chemical compound C1CN(C)CCN1C1=CC(N2C3=CC=C(F)C=C3C=3NN=CC=32)=CC=N1 GZVOXNRYSRNICD-UHFFFAOYSA-N 0.000 claims description 2
- GJZBZIZRWWCQCP-GFCCVEGCSA-N 7-fluoro-4-[2-[(3r)-3-fluoropyrrolidin-1-yl]-4-methylpyrimidin-5-yl]-1h-pyrazolo[4,3-b]indole Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@@H](F)C1 GJZBZIZRWWCQCP-GFCCVEGCSA-N 0.000 claims description 2
- GJZBZIZRWWCQCP-LBPRGKRZSA-N 7-fluoro-4-[2-[(3s)-3-fluoropyrrolidin-1-yl]-4-methylpyrimidin-5-yl]-1h-pyrazolo[4,3-b]indole Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@H](F)C1 GJZBZIZRWWCQCP-LBPRGKRZSA-N 0.000 claims description 2
- SVUSGXJDDQWLGX-UHFFFAOYSA-N 7-fluoro-4-[2-methyl-6-(4-methylpiperazin-1-yl)pyridin-3-yl]-1h-pyrazolo[4,3-b]indole Chemical compound C1CN(C)CCN1C1=CC=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=N1 SVUSGXJDDQWLGX-UHFFFAOYSA-N 0.000 claims description 2
- KCFQVFSOPOVIBQ-UHFFFAOYSA-N 7-fluoro-4-[3-(2-methoxyethyl)-5-methylimidazo[4,5-b]pyridin-6-yl]-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=C(C)N=C2N(CCOC)C=NC2=C1 KCFQVFSOPOVIBQ-UHFFFAOYSA-N 0.000 claims description 2
- WPAIXVACTNYNIE-ZDUSSCGKSA-N 7-fluoro-4-[4-methyl-2-[(3s)-3-methylsulfonylpyrrolidin-1-yl]pyrimidin-5-yl]-1h-pyrazolo[4,3-b]indole Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CC[C@H](S(C)(=O)=O)C1 WPAIXVACTNYNIE-ZDUSSCGKSA-N 0.000 claims description 2
- XFIANOKXLWYJBW-UHFFFAOYSA-N 7-fluoro-4-[5-(methoxymethyl)-1h-pyrazol-4-yl]-1h-pyrazolo[4,3-b]indole Chemical compound N1N=CC(N2C3=CC=C(F)C=C3C=3NN=CC=32)=C1COC XFIANOKXLWYJBW-UHFFFAOYSA-N 0.000 claims description 2
- PAHCDROMZXOPDL-UHFFFAOYSA-N 7-fluoro-6-methyl-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C=2C=C(F)C(C)=CC=2N1C(C(=N1)C)=CC2=C1N=CN2 PAHCDROMZXOPDL-UHFFFAOYSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- 229920002905 Colesevelam Polymers 0.000 claims description 2
- 229920002911 Colestipol Polymers 0.000 claims description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims description 2
- 108010011459 Exenatide Proteins 0.000 claims description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims description 2
- 108010019598 Liraglutide Proteins 0.000 claims description 2
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims description 2
- DTDWYWOXVWNHBF-UHFFFAOYSA-N [1-(difluoromethyl)-4-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)pyrazol-3-yl]methanol Chemical compound OCC1=NN(C(F)F)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 DTDWYWOXVWNHBF-UHFFFAOYSA-N 0.000 claims description 2
- CBZXPJLHIWZSJJ-UHFFFAOYSA-N [1-[5-(7-fluoro-1H-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]azetidin-3-yl]methanol Chemical compound FC1=CC=2C3=C(N(C2C=C1)C=1C(=NC(=NC1)N1CC(C1)CO)C)C=NN3 CBZXPJLHIWZSJJ-UHFFFAOYSA-N 0.000 claims description 2
- JXTQHICBEHRVPQ-UHFFFAOYSA-N [1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperidin-4-yl]methanol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC(CO)CC1 JXTQHICBEHRVPQ-UHFFFAOYSA-N 0.000 claims description 2
- HIZWMLPCMQJIKI-UHFFFAOYSA-N [4-[(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)methyl]phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C(C=C1)=CC=C1CN1C2=CC=C(F)C=C2C2=C1C=NN2 HIZWMLPCMQJIKI-UHFFFAOYSA-N 0.000 claims description 2
- RSFQSOXGJGEZBD-UHFFFAOYSA-N [5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=CC=1C(=O)N1CC(O)C1 RSFQSOXGJGEZBD-UHFFFAOYSA-N 0.000 claims description 2
- ZIDQZVHFJOGZFR-UHFFFAOYSA-N [5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-yl]-morpholin-4-ylmethanone Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=CC=1C(=O)N1CCOCC1 ZIDQZVHFJOGZFR-UHFFFAOYSA-N 0.000 claims description 2
- RGZZJAMJGFBKLH-UHFFFAOYSA-N [5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1C(=O)N1CC(O)C1 RGZZJAMJGFBKLH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002632 acarbose Drugs 0.000 claims description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001466 acetohexamide Drugs 0.000 claims description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001667 alogliptin Drugs 0.000 claims description 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 229960004111 buformin Drugs 0.000 claims description 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims description 2
- 229960001761 chlorpropamide Drugs 0.000 claims description 2
- 229960001214 clofibrate Drugs 0.000 claims description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001152 colesevelam Drugs 0.000 claims description 2
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 2
- 229960002604 colestipol Drugs 0.000 claims description 2
- PBTZDKJBDRBWTN-UHFFFAOYSA-N cyclopropyl-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)methanone Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C(=O)C1CC1 PBTZDKJBDRBWTN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001519 exenatide Drugs 0.000 claims description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
- 229960002297 fenofibrate Drugs 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229960003765 fluvastatin Drugs 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- 229960000346 gliclazide Drugs 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960001381 glipizide Drugs 0.000 claims description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229960002397 linagliptin Drugs 0.000 claims description 2
- 229960002701 liraglutide Drugs 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 229960001110 miglitol Drugs 0.000 claims description 2
- OAJPHLCFGHAQCK-UHFFFAOYSA-N n-(2-amino-2-oxoethyl)-5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NCC(N)=O)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 OAJPHLCFGHAQCK-UHFFFAOYSA-N 0.000 claims description 2
- QFBHPDSTXRPXIU-UHFFFAOYSA-N n-(2-cyanoethyl)-5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)NCCC#N)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 QFBHPDSTXRPXIU-UHFFFAOYSA-N 0.000 claims description 2
- LKWRZFLHHVAZAY-UHFFFAOYSA-N n-(cyanomethyl)-5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-n,6-dimethylpyridine-2-carboxamide Chemical compound CC1=NC(C(=O)N(CC#N)C)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 LKWRZFLHHVAZAY-UHFFFAOYSA-N 0.000 claims description 2
- AEMBWZZXYUVYPH-UHFFFAOYSA-N n-benzyl-7-fluoro-1h-pyrazolo[4,3-b]indole-4-carboxamide Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C(=O)NCC1=CC=CC=C1 AEMBWZZXYUVYPH-UHFFFAOYSA-N 0.000 claims description 2
- PYQYJBHXWRJLPK-UHFFFAOYSA-N n-cyclopropyl-5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridine-2-carboxamide Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1C(=O)NC1CC1 PYQYJBHXWRJLPK-UHFFFAOYSA-N 0.000 claims description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 2
- 229960000698 nateglinide Drugs 0.000 claims description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 2
- 229960001243 orlistat Drugs 0.000 claims description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims description 2
- 229960003243 phenformin Drugs 0.000 claims description 2
- 229960005095 pioglitazone Drugs 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 229960002354 repaglinide Drugs 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 2
- 229960004937 saxagliptin Drugs 0.000 claims description 2
- 108010033693 saxagliptin Proteins 0.000 claims description 2
- 229960004034 sitagliptin Drugs 0.000 claims description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims description 2
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 claims description 2
- 229950007151 taspoglutide Drugs 0.000 claims description 2
- 108010048573 taspoglutide Proteins 0.000 claims description 2
- 229960002277 tolazamide Drugs 0.000 claims description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005371 tolbutamide Drugs 0.000 claims description 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims description 2
- 229960001254 vildagliptin Drugs 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- RJMOCFHZZVNPMG-UHFFFAOYSA-N 2-[6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methylimidazo[4,5-b]pyridin-3-yl]ethanol Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(N=CN2CCO)=C2N=C1C RJMOCFHZZVNPMG-UHFFFAOYSA-N 0.000 claims 1
- FPGGLMIYNLQOID-UHFFFAOYSA-N 3h-pyridin-2-one Chemical compound O=C1CC=CC=N1 FPGGLMIYNLQOID-UHFFFAOYSA-N 0.000 claims 1
- OWDFYKWZCMOMNL-UHFFFAOYSA-N 4-(5-ethyl-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazin-3-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C(C=N1)=C2N1CCN(CC)C2 OWDFYKWZCMOMNL-UHFFFAOYSA-N 0.000 claims 1
- RIKBSXGPFCVVMD-UHFFFAOYSA-N 4-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-6-methylpyridin-2-yl]morpholine Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCOCC1 RIKBSXGPFCVVMD-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- NRCFQLGHARGZHK-CYBMUJFWSA-N [5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyridin-2-yl]-[(3r)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=CC=1C(=O)N1CC[C@@H](O)C1 NRCFQLGHARGZHK-CYBMUJFWSA-N 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 229960000815 ezetimibe Drugs 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 273
- 238000005481 NMR spectroscopy Methods 0.000 description 145
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 131
- 235000019439 ethyl acetate Nutrition 0.000 description 129
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 121
- 239000000203 mixture Substances 0.000 description 101
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 99
- 238000002360 preparation method Methods 0.000 description 94
- 239000011541 reaction mixture Substances 0.000 description 90
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 86
- 239000000243 solution Substances 0.000 description 80
- 239000007787 solid Substances 0.000 description 68
- 239000010410 layer Substances 0.000 description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- 239000012044 organic layer Substances 0.000 description 61
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 56
- ZZFKQUTYXXPQBS-UHFFFAOYSA-N 6-bromo-5-methyl-1h-imidazo[4,5-b]pyridine Chemical compound C1=C(Br)C(C)=NC2=C1NC=N2 ZZFKQUTYXXPQBS-UHFFFAOYSA-N 0.000 description 47
- 239000012267 brine Substances 0.000 description 44
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 238000003756 stirring Methods 0.000 description 42
- 239000011734 sodium Substances 0.000 description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 239000002904 solvent Substances 0.000 description 39
- 238000012360 testing method Methods 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 239000000725 suspension Substances 0.000 description 29
- JPBCOHGBRRIGPI-UHFFFAOYSA-N 4-(5-bromo-6-methylpyridin-2-yl)morpholine Chemical compound C1=C(Br)C(C)=NC(N2CCOCC2)=C1 JPBCOHGBRRIGPI-UHFFFAOYSA-N 0.000 description 27
- 238000002953 preparative HPLC Methods 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000009472 formulation Methods 0.000 description 26
- 238000000746 purification Methods 0.000 description 26
- 239000006188 syrup Substances 0.000 description 26
- 235000020357 syrup Nutrition 0.000 description 26
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 25
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 23
- 238000003818 flash chromatography Methods 0.000 description 21
- 239000002253 acid Substances 0.000 description 19
- 239000003921 oil Substances 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- 239000002552 dosage form Substances 0.000 description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- SQDGORBUIPHRHE-UHFFFAOYSA-N 7-fluoro-1-(oxan-2-yl)-4H-pyrazolo[4,3-b]indole Chemical compound FC1=CC=2C3=C(NC2C=C1)C=NN3C3OCCCC3 SQDGORBUIPHRHE-UHFFFAOYSA-N 0.000 description 17
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 239000012453 solvate Substances 0.000 description 16
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 239000003826 tablet Substances 0.000 description 15
- 239000010408 film Substances 0.000 description 14
- IQHXABCGSFAKPN-SCSAIBSYSA-N (3r)-pyrrolidine-3-carboxamide Chemical compound NC(=O)[C@@H]1CCNC1 IQHXABCGSFAKPN-SCSAIBSYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 241000209140 Triticum Species 0.000 description 12
- 235000021307 Triticum Nutrition 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 11
- IIALSLVGUGOODS-UHFFFAOYSA-N 5-bromo-2-chloro-4-methylpyrimidine Chemical compound CC1=NC(Cl)=NC=C1Br IIALSLVGUGOODS-UHFFFAOYSA-N 0.000 description 10
- ULEMJGCUGKDKTD-UHFFFAOYSA-N [1-(hydroxymethyl)cyclopropyl]azanium;chloride Chemical compound Cl.OCC1(N)CC1 ULEMJGCUGKDKTD-UHFFFAOYSA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 239000003208 petroleum Substances 0.000 description 10
- 125000006413 ring segment Chemical group 0.000 description 10
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- 239000007821 HATU Substances 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 150000004677 hydrates Chemical class 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229910000104 sodium hydride Inorganic materials 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- AYBYXVSLEOHSBO-ZETCQYMHSA-N (3s)-1-(5-bromo-4-methylpyrimidin-2-yl)pyrrolidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](O)CC2)=N1 AYBYXVSLEOHSBO-ZETCQYMHSA-N 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- LMHIBYREWJHKNZ-UHFFFAOYSA-N 3-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CN=C1C(O)=O LMHIBYREWJHKNZ-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HXOYWCSTHVTLOW-YFKPBYRVSA-N [(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methanamine Chemical compound CC1(C)OC[C@H](CN)O1 HXOYWCSTHVTLOW-YFKPBYRVSA-N 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PRQAIVKHRVEJPG-JEDNCBNOSA-N (2s)-n-methylpyrrolidine-2-carboxamide;hydrochloride Chemical compound Cl.CNC(=O)[C@@H]1CCCN1 PRQAIVKHRVEJPG-JEDNCBNOSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- NLEZSQHAFMZAGU-UHFFFAOYSA-N 2-bromo-5-chloroaniline Chemical compound NC1=CC(Cl)=CC=C1Br NLEZSQHAFMZAGU-UHFFFAOYSA-N 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- KPQPKJUTQXGDAY-UHFFFAOYSA-N 4-[[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CN1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 KPQPKJUTQXGDAY-UHFFFAOYSA-N 0.000 description 4
- UNTQXOJGXGRHMG-UHFFFAOYSA-N 4-bromo-1,3,5-trimethylpyrazole Chemical compound CC1=NN(C)C(C)=C1Br UNTQXOJGXGRHMG-UHFFFAOYSA-N 0.000 description 4
- WOCJPCULGXUBJF-QMMMGPOBSA-N 5-bromo-n-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-6-methyl-3-nitropyridin-2-amine Chemical compound C1=C(Br)C(C)=NC(NC[C@@H]2OC(C)(C)OC2)=C1[N+]([O-])=O WOCJPCULGXUBJF-QMMMGPOBSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Chemical group 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000010926 purge Methods 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000011593 sulfur Chemical group 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 3
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UPTXJQUFDOYWJO-UHFFFAOYSA-N 1-(5-bromo-4-methylpyrimidin-2-yl)piperidin-4-ol Chemical compound C1=C(Br)C(C)=NC(N2CCC(O)CC2)=N1 UPTXJQUFDOYWJO-UHFFFAOYSA-N 0.000 description 3
- SQINZNNGOZLMBC-UHFFFAOYSA-N 2,5-dibromo-6-methyl-3-nitropyridine Chemical compound CC1=NC(Br)=C([N+]([O-])=O)C=C1Br SQINZNNGOZLMBC-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- JQAYDGZDCJZHNB-UHFFFAOYSA-N 2-(6-bromo-5-methylimidazo[4,5-b]pyridin-3-yl)ethanol Chemical compound C1=C(Br)C(C)=NC2=C1N=CN2CCO JQAYDGZDCJZHNB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- YOMDXZMZLPOYNG-UHFFFAOYSA-N 2-[[4-bromo-5-(methoxymethyl)pyrazol-1-yl]methoxy]ethyl-trimethylsilane Chemical compound COCC1=C(Br)C=NN1COCC[Si](C)(C)C YOMDXZMZLPOYNG-UHFFFAOYSA-N 0.000 description 3
- JVHDWGXUVNSHAB-UHFFFAOYSA-N 4-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 JVHDWGXUVNSHAB-UHFFFAOYSA-N 0.000 description 3
- MOUGDWFJPYOCSB-UHFFFAOYSA-N 5-bromo-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(N)=O)C=C1Br MOUGDWFJPYOCSB-UHFFFAOYSA-N 0.000 description 3
- QLYDIHRYOAQXJT-UHFFFAOYSA-N 5-bromo-1-methylpyrazole-3-carboxylic acid Chemical compound CN1N=C(C(O)=O)C=C1Br QLYDIHRYOAQXJT-UHFFFAOYSA-N 0.000 description 3
- DOUIXQNDLHYGEY-QMMMGPOBSA-N 5-bromo-2-n-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-6-methylpyridine-2,3-diamine Chemical compound C1=C(Br)C(C)=NC(NC[C@@H]2OC(C)(C)OC2)=C1N DOUIXQNDLHYGEY-QMMMGPOBSA-N 0.000 description 3
- MVEUCAYEKFZDEG-UHFFFAOYSA-N 6-bromo-5-methyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound C1=C(Br)C(C)=NC2=C1NC(=O)N2 MVEUCAYEKFZDEG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- PPIPVPHFSAPSRR-UHFFFAOYSA-N [4-bromo-2-(2-trimethylsilylethoxymethyl)pyrazol-3-yl]methanol Chemical compound C[Si](C)(C)CCOCN1N=CC(Br)=C1CO PPIPVPHFSAPSRR-UHFFFAOYSA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- SFJMFSWCBVEHBA-UHFFFAOYSA-M copper(i)-thiophene-2-carboxylate Chemical compound [Cu+].[O-]C(=O)C1=CC=CS1 SFJMFSWCBVEHBA-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- FOKOPSYMIANKID-UHFFFAOYSA-N methyl 3-(6-bromo-5-methyl-2-oxo-1h-imidazo[4,5-b]pyridin-3-yl)propanoate Chemical compound CC1=C(Br)C=C2NC(=O)N(CCC(=O)OC)C2=N1 FOKOPSYMIANKID-UHFFFAOYSA-N 0.000 description 3
- PQUPJFXVHNSJDW-UHFFFAOYSA-N methyl 3-[(3-amino-5-bromo-6-methylpyridin-2-yl)amino]propanoate Chemical compound COC(=O)CCNC1=NC(C)=C(Br)C=C1N PQUPJFXVHNSJDW-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical class [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 238000012746 preparative thin layer chromatography Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- ACRBKOHPXSQXGG-UMPGHQJDSA-N (1r,5s)-3-(5-bromo-4-methylpyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound C1=C(Br)C(C)=NC(N2C([C@@H]3C[C@@H]3C2)C(N)=O)=N1 ACRBKOHPXSQXGG-UMPGHQJDSA-N 0.000 description 2
- WZEIBMJVGONJCT-RXMQYKEDSA-N (2r)-1-[(5-bromo-4-methylpyrimidin-2-yl)amino]propan-2-ol Chemical compound C[C@@H](O)CNC1=NC=C(Br)C(C)=N1 WZEIBMJVGONJCT-RXMQYKEDSA-N 0.000 description 2
- VPTOVQBZCLZYOK-RXMQYKEDSA-N (2r)-2-[(5-bromo-4-methylpyrimidin-2-yl)amino]propan-1-ol Chemical compound OC[C@@H](C)NC1=NC=C(Br)C(C)=N1 VPTOVQBZCLZYOK-RXMQYKEDSA-N 0.000 description 2
- WZEIBMJVGONJCT-YFKPBYRVSA-N (2s)-1-[(5-bromo-4-methylpyrimidin-2-yl)amino]propan-2-ol Chemical compound C[C@H](O)CNC1=NC=C(Br)C(C)=N1 WZEIBMJVGONJCT-YFKPBYRVSA-N 0.000 description 2
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 2
- VPTOVQBZCLZYOK-YFKPBYRVSA-N (2s)-2-[(5-bromo-4-methylpyrimidin-2-yl)amino]propan-1-ol Chemical compound OC[C@H](C)NC1=NC=C(Br)C(C)=N1 VPTOVQBZCLZYOK-YFKPBYRVSA-N 0.000 description 2
- UPJRUZXNSOFFEJ-ZCFIWIBFSA-N (3r)-1-(5-bromo-4-methoxypyrimidin-2-yl)pyrrolidin-3-ol Chemical compound C1=C(Br)C(OC)=NC(N2C[C@H](O)CC2)=N1 UPJRUZXNSOFFEJ-ZCFIWIBFSA-N 0.000 description 2
- QMWQFGWQVVHFEF-MRVPVSSYSA-N (3r)-1-(5-bromo-4-methylpyrimidin-2-yl)piperidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](O)CCC2)=N1 QMWQFGWQVVHFEF-MRVPVSSYSA-N 0.000 description 2
- HNPQRZHQNHCEEX-MRVPVSSYSA-N (3r)-1-(5-bromo-6-methylpyridin-2-yl)pyrrolidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](O)CC2)=C1 HNPQRZHQNHCEEX-MRVPVSSYSA-N 0.000 description 2
- PJORUDYWOVMHCG-HTQZYQBOSA-N (3r,4r)-1-(5-bromo-4-methylpyrimidin-2-yl)pyrrolidine-3,4-diol Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](O)[C@H](O)C2)=N1 PJORUDYWOVMHCG-HTQZYQBOSA-N 0.000 description 2
- QMWQFGWQVVHFEF-QMMMGPOBSA-N (3s)-1-(5-bromo-4-methylpyrimidin-2-yl)piperidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](O)CCC2)=N1 QMWQFGWQVVHFEF-QMMMGPOBSA-N 0.000 description 2
- LOWGMRWMZATDDS-ZETCQYMHSA-N (3s)-1-(5-bromo-4-methylpyrimidin-2-yl)pyrrolidine-3-carboxylic acid Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](CC2)C(O)=O)=N1 LOWGMRWMZATDDS-ZETCQYMHSA-N 0.000 description 2
- HNPQRZHQNHCEEX-QMMMGPOBSA-N (3s)-1-(5-bromo-6-methylpyridin-2-yl)pyrrolidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](O)CC2)=C1 HNPQRZHQNHCEEX-QMMMGPOBSA-N 0.000 description 2
- JANKYZWJRNMSGW-ZDGMYTEDSA-N (3s)-1-[5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-4-methylpyrimidin-2-yl]pyrrolidine-3-carboxylic acid Chemical compound CC1=NC(N2C[C@H](CC2)C(O)=O)=NC=C1N(C1=CC=C(F)C=C1C=12)C=1C=NN2C1CCCCO1 JANKYZWJRNMSGW-ZDGMYTEDSA-N 0.000 description 2
- QPMSJEFZULFYTB-WCCKRBBISA-N (3s)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@H]1CCNC1 QPMSJEFZULFYTB-WCCKRBBISA-N 0.000 description 2
- PCVKEOQZVDCNGO-UHFFFAOYSA-N 1-(4-bromopyridin-2-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC(Br)=CC=N1 PCVKEOQZVDCNGO-UHFFFAOYSA-N 0.000 description 2
- OMJDJFPCKYPEAP-UHFFFAOYSA-N 1-(5-bromo-4-methylpyrimidin-2-yl)azetidin-3-ol Chemical compound C1=C(Br)C(C)=NC(N2CC(O)C2)=N1 OMJDJFPCKYPEAP-UHFFFAOYSA-N 0.000 description 2
- WHSLCLOMSJQONW-UHFFFAOYSA-N 1-(5-bromo-6-methylpyridin-2-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(Br)C(C)=N1 WHSLCLOMSJQONW-UHFFFAOYSA-N 0.000 description 2
- ZZRFDLHBMBHJTI-UHFFFAOYSA-N 1-(oxan-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=NN1C1OCCCC1 ZZRFDLHBMBHJTI-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- MZJSXPJOTBZLEC-UHFFFAOYSA-N 1-azido-2-bromo-4-fluorobenzene Chemical compound FC1=CC=C(N=[N+]=[N-])C(Br)=C1 MZJSXPJOTBZLEC-UHFFFAOYSA-N 0.000 description 2
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 2
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- JXXHELLXPNUXNS-UHFFFAOYSA-N 2-[(5-bromo-4-methylpyrimidin-2-yl)amino]ethanol Chemical compound CC1=NC(NCCO)=NC=C1Br JXXHELLXPNUXNS-UHFFFAOYSA-N 0.000 description 2
- BUTIDJREEDINSI-UHFFFAOYSA-N 2-bromo-4,5-difluoroaniline Chemical compound NC1=CC(F)=C(F)C=C1Br BUTIDJREEDINSI-UHFFFAOYSA-N 0.000 description 2
- YLMFXCIATJJKQL-UHFFFAOYSA-N 2-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Br YLMFXCIATJJKQL-UHFFFAOYSA-N 0.000 description 2
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 2
- CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 2
- DTFBHJWQTDQBEM-UHFFFAOYSA-N 3-bromo-6-chloro-2-methylpyridine Chemical compound CC1=NC(Cl)=CC=C1Br DTFBHJWQTDQBEM-UHFFFAOYSA-N 0.000 description 2
- GUYGQQWIKZLHTP-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methylpyridine Chemical compound CC1=NC(F)=CC=C1Br GUYGQQWIKZLHTP-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- CTVHVIMJEWKEDB-UHFFFAOYSA-N 4-(5-bromo-4-methylpyrimidin-2-yl)-1-methylpiperazin-2-one Chemical compound C1C(=O)N(C)CCN1C1=NC=C(Br)C(C)=N1 CTVHVIMJEWKEDB-UHFFFAOYSA-N 0.000 description 2
- QQDNKPWCJFZNFO-UHFFFAOYSA-N 4-(5-bromo-4-methylpyrimidin-2-yl)piperazin-2-one Chemical compound C1=C(Br)C(C)=NC(N2CC(=O)NCC2)=N1 QQDNKPWCJFZNFO-UHFFFAOYSA-N 0.000 description 2
- LNOZCTUTXJOUED-UHFFFAOYSA-N 4-(6-chloro-2-methylpyridin-3-yl)-7-fluoro-1h-pyrazolo[4,3-b]indole Chemical compound CC1=NC(Cl)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 LNOZCTUTXJOUED-UHFFFAOYSA-N 0.000 description 2
- VGQYGJXBIRIZQJ-UHFFFAOYSA-N 4-azido-5-phenyl-1h-pyrazole Chemical compound [N-]=[N+]=NC1=CNN=C1C1=CC=CC=C1 VGQYGJXBIRIZQJ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- MEGJBZQUESCFJW-UHFFFAOYSA-N 5-(2-azido-4-chlorophenyl)-1-(oxan-2-yl)pyrazole Chemical compound [N-]=[N+]=NC1=CC(Cl)=CC=C1C1=CC=NN1C1OCCCC1 MEGJBZQUESCFJW-UHFFFAOYSA-N 0.000 description 2
- SWPWSMQXHZRWQK-UHFFFAOYSA-N 5-(2-azido-5-fluorophenyl)-1-(oxan-2-yl)pyrazole Chemical compound FC1=CC=C(N=[N+]=[N-])C(C=2N(N=CC=2)C2OCCCC2)=C1 SWPWSMQXHZRWQK-UHFFFAOYSA-N 0.000 description 2
- QILAUUVGKUOFGA-UHFFFAOYSA-N 5-bromo-2-(3,3-difluoroazetidin-1-yl)-4-methylpyrimidine Chemical compound C1=C(Br)C(C)=NC(N2CC(F)(F)C2)=N1 QILAUUVGKUOFGA-UHFFFAOYSA-N 0.000 description 2
- QCRHGKHNLRIIGG-SSDOTTSWSA-N 5-bromo-2-[(3r)-3-fluoropyrrolidin-1-yl]-4-methylpyrimidine Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](F)CC2)=N1 QCRHGKHNLRIIGG-SSDOTTSWSA-N 0.000 description 2
- QCRHGKHNLRIIGG-ZETCQYMHSA-N 5-bromo-2-[(3s)-3-fluoropyrrolidin-1-yl]-4-methylpyrimidine Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](F)CC2)=N1 QCRHGKHNLRIIGG-ZETCQYMHSA-N 0.000 description 2
- DOUIXQNDLHYGEY-MRVPVSSYSA-N 5-bromo-2-n-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-6-methylpyridine-2,3-diamine Chemical compound C1=C(Br)C(C)=NC(NC[C@H]2OC(C)(C)OC2)=C1N DOUIXQNDLHYGEY-MRVPVSSYSA-N 0.000 description 2
- NJZHCKUETBNUJT-UHFFFAOYSA-N 5-bromo-4-methyl-2-(4-methylpiperazin-1-yl)pyrimidine Chemical compound C1CN(C)CCN1C1=NC=C(Br)C(C)=N1 NJZHCKUETBNUJT-UHFFFAOYSA-N 0.000 description 2
- MGNKHLNAUDGVMO-QMMMGPOBSA-N 5-bromo-4-methyl-2-[(3s)-3-methylsulfonylpyrrolidin-1-yl]pyrimidine Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](CC2)S(C)(=O)=O)=N1 MGNKHLNAUDGVMO-QMMMGPOBSA-N 0.000 description 2
- NQEWSHYEOWDGEO-UHFFFAOYSA-N 5-bromo-n-(2-hydroxyethyl)-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCCO)C=C1Br NQEWSHYEOWDGEO-UHFFFAOYSA-N 0.000 description 2
- TUWHEEGSQTUKHL-UHFFFAOYSA-N 6-bromo-3,5-dimethylimidazo[4,5-b]pyridine Chemical compound C1=C(Br)C(C)=NC2=C1N=CN2C TUWHEEGSQTUKHL-UHFFFAOYSA-N 0.000 description 2
- DQENSNGCIAQHHQ-UHFFFAOYSA-N 6-bromo-3-ethyl-5-methylimidazo[4,5-b]pyridine Chemical compound BrC1=C(C)N=C2N(CC)C=NC2=C1 DQENSNGCIAQHHQ-UHFFFAOYSA-N 0.000 description 2
- NMGVYEHUHRPWJK-UHFFFAOYSA-N 7-fluoro-4-(5-methyl-1h-imidazo[4,5-b]pyridin-6-yl)-1-(oxan-2-yl)pyrazolo[4,3-b]indole Chemical compound CC1=NC=2N=CNC=2C=C1N(C1=CC=C(F)C=C1C=12)C=1C=NN2C1CCCCO1 NMGVYEHUHRPWJK-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- 229910010082 LiAlH Inorganic materials 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- IHNPGTWIJMFHAK-MRVPVSSYSA-N [(2r)-4-(5-bromo-4-methylpyrimidin-2-yl)morpholin-2-yl]methanol Chemical compound C1=C(Br)C(C)=NC(N2C[C@H](CO)OCC2)=N1 IHNPGTWIJMFHAK-MRVPVSSYSA-N 0.000 description 2
- IHNPGTWIJMFHAK-QMMMGPOBSA-N [(2s)-4-(5-bromo-4-methylpyrimidin-2-yl)morpholin-2-yl]methanol Chemical compound C1=C(Br)C(C)=NC(N2C[C@@H](CO)OCC2)=N1 IHNPGTWIJMFHAK-QMMMGPOBSA-N 0.000 description 2
- HXOYWCSTHVTLOW-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanamine Chemical compound CC1(C)OC[C@@H](CN)O1 HXOYWCSTHVTLOW-RXMQYKEDSA-N 0.000 description 2
- GTXWDRUFGVADMP-UHFFFAOYSA-N [1-(5-bromo-4-methylpyrimidin-2-yl)azetidin-3-yl]methanol Chemical compound C1=C(Br)C(C)=NC(N2CC(CO)C2)=N1 GTXWDRUFGVADMP-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 229910001429 cobalt ion Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical class 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- TYRHOAJJVZJDTA-UHFFFAOYSA-N ethyl 2-[(3-amino-5-bromo-6-methylpyridin-2-yl)amino]acetate Chemical compound CCOC(=O)CNC1=NC(C)=C(Br)C=C1N TYRHOAJJVZJDTA-UHFFFAOYSA-N 0.000 description 2
- MJAHHURFTZJVKT-UHFFFAOYSA-N ethyl 4-bromo-1-(difluoromethyl)pyrazole-3-carboxylate Chemical compound CCOC(=O)C1=NN(C(F)F)C=C1Br MJAHHURFTZJVKT-UHFFFAOYSA-N 0.000 description 2
- YTIXVTQCUMGIBZ-UHFFFAOYSA-N ethyl 4-bromo-1h-pyrazole-5-carboxylate Chemical compound CCOC(=O)C=1NN=CC=1Br YTIXVTQCUMGIBZ-UHFFFAOYSA-N 0.000 description 2
- ICSAMWWFSLVJGE-UHFFFAOYSA-N ethyl 6-bromo-5-methyl-2-oxo-3h-imidazo[4,5-b]pyridine-1-carboxylate Chemical compound BrC1=C(C)N=C2NC(=O)N(C(=O)OCC)C2=C1 ICSAMWWFSLVJGE-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 230000002535 lyotropic effect Effects 0.000 description 2
- 229910001437 manganese ion Inorganic materials 0.000 description 2
- 229960003963 manidipine Drugs 0.000 description 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
- UZCXPYDBYUEZCV-UHFFFAOYSA-N methyl 3-aminopropanoate Chemical compound COC(=O)CCN UZCXPYDBYUEZCV-UHFFFAOYSA-N 0.000 description 2
- NLWBJPPMPLPZIE-UHFFFAOYSA-N methyl 4-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=C(CBr)C=C1 NLWBJPPMPLPZIE-UHFFFAOYSA-N 0.000 description 2
- BJFGLPMFBXEFNW-UHFFFAOYSA-N methyl 4-[[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]methyl]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1CN1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 BJFGLPMFBXEFNW-UHFFFAOYSA-N 0.000 description 2
- KWQDACZQHJCUNK-UHFFFAOYSA-N methyl 4-bromo-1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1NN=CC=1Br KWQDACZQHJCUNK-UHFFFAOYSA-N 0.000 description 2
- BCCZQVDKGKYULJ-UHFFFAOYSA-N methyl 4-bromo-2-(2-trimethylsilylethoxymethyl)pyrazole-3-carboxylate Chemical compound COC(=O)C1=C(Br)C=NN1COCC[Si](C)(C)C BCCZQVDKGKYULJ-UHFFFAOYSA-N 0.000 description 2
- CZNGTXVOZOWWKM-UHFFFAOYSA-N methyl 4-bromobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1 CZNGTXVOZOWWKM-UHFFFAOYSA-N 0.000 description 2
- WNUFTWCRMKYPKE-UHFFFAOYSA-N methyl 5-bromo-4-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC(C)=C(Br)C=N1 WNUFTWCRMKYPKE-UHFFFAOYSA-N 0.000 description 2
- 229940095102 methyl benzoate Drugs 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- HDZDIXBTYZYSCW-UHFFFAOYSA-N tert-butyl 6-bromo-1-(2-hydroxyethyl)-5-methyl-2-oxoimidazo[4,5-b]pyridine-3-carboxylate Chemical compound C1=C(Br)C(C)=NC2=C1N(CCO)C(=O)N2C(=O)OC(C)(C)C HDZDIXBTYZYSCW-UHFFFAOYSA-N 0.000 description 2
- QWEIHUURQLJUSZ-UHFFFAOYSA-N tert-butyl 6-bromo-5-methyl-2-oxo-1h-imidazo[4,5-b]pyridine-3-carboxylate Chemical compound C1=C(Br)C(C)=NC2=C1NC(=O)N2C(=O)OC(C)(C)C QWEIHUURQLJUSZ-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- YSFYTAHQPMGPOO-UMPGHQJDSA-N (1r,5s)-3-(5-bromo-4-methylpyrimidin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid Chemical compound C1=C(Br)C(C)=NC(N2C([C@@H]3C[C@@H]3C2)C(O)=O)=N1 YSFYTAHQPMGPOO-UMPGHQJDSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- TWTUMFQPQOJUHK-HNNXBMFYSA-N (2S)-1-[5-(7-fluoro-1H-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]-N-methylpyrrolidine-2-carboxamide Chemical compound FC1=CC=2C3=C(N(C2C=C1)C=1C(=NC(=NC1)N1[C@@H](CCC1)C(=O)NC)C)C=NN3 TWTUMFQPQOJUHK-HNNXBMFYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OLCCMMRELVLAOS-ZCFIWIBFSA-N (2r)-1-[(5-bromo-6-methylpyridin-2-yl)amino]propan-2-ol Chemical compound C[C@@H](O)CNC1=CC=C(Br)C(C)=N1 OLCCMMRELVLAOS-ZCFIWIBFSA-N 0.000 description 1
- XFLZIIASAHFMPT-SECBINFHSA-N (2r)-2-[[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]amino]propan-1-ol Chemical compound CC1=NC(N[C@@H](CO)C)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2 XFLZIIASAHFMPT-SECBINFHSA-N 0.000 description 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- VLJNHYLEOZPXFW-SCSAIBSYSA-N (2r)-pyrrolidine-2-carboxamide Chemical compound NC(=O)[C@H]1CCCN1 VLJNHYLEOZPXFW-SCSAIBSYSA-N 0.000 description 1
- BAVDEDVBIHTHJQ-UVJOBNTFSA-N (2s)-1-[(2s)-6-amino-2-[[(1s)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid;hydrate Chemical compound O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 BAVDEDVBIHTHJQ-UVJOBNTFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- XNEHPONZIPWIPY-CQSZACIVSA-N (3r)-1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]-n,n-dimethylpyrrolidin-3-amine Chemical compound C1[C@H](N(C)C)CCN1C1=NC=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=N1 XNEHPONZIPWIPY-CQSZACIVSA-N 0.000 description 1
- LENYOXXELREKGZ-PGMHMLKASA-N (3r)-3-fluoropyrrolidine;hydrochloride Chemical compound Cl.F[C@@H]1CCNC1 LENYOXXELREKGZ-PGMHMLKASA-N 0.000 description 1
- AVAWMINJNRAQFS-ZCFIWIBFSA-N (3r)-n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)[C@@H]1CCNC1 AVAWMINJNRAQFS-ZCFIWIBFSA-N 0.000 description 1
- VLECDMDGMKPUSK-NUBCRITNSA-N (3r)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCCNC1 VLECDMDGMKPUSK-NUBCRITNSA-N 0.000 description 1
- JCZPOYAMKJFOLA-QWWZWVQMSA-N (3r,4r)-pyrrolidine-3,4-diol Chemical compound O[C@@H]1CNC[C@H]1O JCZPOYAMKJFOLA-QWWZWVQMSA-N 0.000 description 1
- IHNVEHPURMHIKZ-BJQOMGFOSA-N (3s)-1-[5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-4-methylpyrimidin-2-yl]pyrrolidin-3-ol Chemical compound CC1=NC(N2C[C@@H](O)CC2)=NC=C1N(C1=CC=C(F)C=C1C=12)C=1C=NN2C1CCCCO1 IHNVEHPURMHIKZ-BJQOMGFOSA-N 0.000 description 1
- LENYOXXELREKGZ-WCCKRBBISA-N (3s)-3-fluoropyrrolidin-1-ium;chloride Chemical compound Cl.F[C@H]1CCNC1 LENYOXXELREKGZ-WCCKRBBISA-N 0.000 description 1
- XCEGFNRUBBVHJT-YFKPBYRVSA-N (3s)-3-methylsulfonylpyrrolidine Chemical compound CS(=O)(=O)[C@H]1CCNC1 XCEGFNRUBBVHJT-YFKPBYRVSA-N 0.000 description 1
- VLECDMDGMKPUSK-JEDNCBNOSA-N (3s)-piperidin-3-ol;hydrochloride Chemical compound Cl.O[C@H]1CCCNC1 VLECDMDGMKPUSK-JEDNCBNOSA-N 0.000 description 1
- IQHXABCGSFAKPN-BYPYZUCNSA-N (3s)-pyrrolidine-3-carboxamide Chemical compound NC(=O)[C@H]1CCNC1 IQHXABCGSFAKPN-BYPYZUCNSA-N 0.000 description 1
- OYCLYMMIZJWYJG-WCCKRBBISA-N (3s)-pyrrolidine-3-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)[C@H]1CCNC1 OYCLYMMIZJWYJG-WCCKRBBISA-N 0.000 description 1
- WRRSFOZOETZUPG-FFHNEAJVSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;hydrate Chemical compound O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC WRRSFOZOETZUPG-FFHNEAJVSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- RAHREESPEKBGIO-UHFFFAOYSA-N 1-(5-bromo-4-methylpyrimidin-2-yl)azetidine-3-carboxamide Chemical compound C1=C(Br)C(C)=NC(N2CC(C2)C(N)=O)=N1 RAHREESPEKBGIO-UHFFFAOYSA-N 0.000 description 1
- YDTHXIFPWDWGQJ-UHFFFAOYSA-N 1-(5-bromo-6-methylpyridin-2-yl)piperazine;hydrochloride Chemical compound Cl.C1=C(Br)C(C)=NC(N2CCNCC2)=C1 YDTHXIFPWDWGQJ-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- IFVRHEZPPGYBSV-UHFFFAOYSA-N 1-[5-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-4-methylpyrimidin-2-yl]piperidin-4-ol Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC(O)CC1 IFVRHEZPPGYBSV-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- CRRUGYDDEMGVDY-UHFFFAOYSA-N 1-bromoethylbenzene Chemical compound CC(Br)C1=CC=CC=C1 CRRUGYDDEMGVDY-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- DKWNYTKOLIZNAX-UHFFFAOYSA-N 1-chloro-2-methylsulfonylethane Chemical compound CS(=O)(=O)CCCl DKWNYTKOLIZNAX-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KMRWHESBJZFGFH-UHFFFAOYSA-N 1-methylpiperazin-2-one;hydrochloride Chemical compound Cl.CN1CCNCC1=O KMRWHESBJZFGFH-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- PVVRRUUMHFWFQV-UHFFFAOYSA-N 2-(methylamino)acetonitrile Chemical compound CNCC#N PVVRRUUMHFWFQV-UHFFFAOYSA-N 0.000 description 1
- GHCFWKFREBNSPC-UHFFFAOYSA-N 2-Amino-4-methylpyrimidine Chemical compound CC1=CC=NC(N)=N1 GHCFWKFREBNSPC-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- ALKKMCXRUDTQLC-UHFFFAOYSA-N 2-[(5-bromo-4-methylpyridin-2-yl)-methylamino]ethanol Chemical compound OCCN(C)C1=CC(C)=C(Br)C=N1 ALKKMCXRUDTQLC-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- FBMYKMYQHCBIGU-UHFFFAOYSA-N 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile Chemical compound C=1NC2=CC=CC=C2C=1CC(C)(C)NCC(O)COC1=CC=CC=C1C#N FBMYKMYQHCBIGU-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- SOLCGTLCIBOSQW-UHFFFAOYSA-N 2-acetyloxyethylazanium;chloride Chemical compound Cl.CC(=O)OCCN SOLCGTLCIBOSQW-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- ZKMFNQWRALCSTP-UHFFFAOYSA-N 2-azido-1-bromo-4-chlorobenzene Chemical compound ClC1=CC=C(Br)C(N=[N+]=[N-])=C1 ZKMFNQWRALCSTP-UHFFFAOYSA-N 0.000 description 1
- IGDQOIBCFYWRBZ-UHFFFAOYSA-N 2-azido-1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C(N=[N+]=[N-])=C1 IGDQOIBCFYWRBZ-UHFFFAOYSA-N 0.000 description 1
- TVGJGCSBDAWDTG-UHFFFAOYSA-N 2-bromo-4-fluoro-5-methylaniline Chemical compound CC1=CC(N)=C(Br)C=C1F TVGJGCSBDAWDTG-UHFFFAOYSA-N 0.000 description 1
- QNKQNJJCNWUOHC-UHFFFAOYSA-N 2-bromo-5-chloro-4-fluoroaniline Chemical compound NC1=CC(Cl)=C(F)C=C1Br QNKQNJJCNWUOHC-UHFFFAOYSA-N 0.000 description 1
- SOHDPICLICFSOP-UHFFFAOYSA-N 2-bromo-6-methylpyridine Chemical compound CC1=CC=CC(Br)=N1 SOHDPICLICFSOP-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- DQMKTPZJMGYCLE-UHFFFAOYSA-N 2-bromopyrazole-3-carboxylic acid Chemical compound BrN1N=CC=C1C(=O)O DQMKTPZJMGYCLE-UHFFFAOYSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-MICDWDOJSA-N 2-deuterioacetonitrile Chemical compound [2H]CC#N WEVYAHXRMPXWCK-MICDWDOJSA-N 0.000 description 1
- WYURNTSHIVDZCO-WFVSFCRTSA-N 2-deuteriooxolane Chemical compound [2H]C1CCCO1 WYURNTSHIVDZCO-WFVSFCRTSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- 229940093475 2-ethoxyethanol Drugs 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- YGRQDAPOAQBGJC-NSHDSACASA-N 3-[(2s)-2,3-dihydroxypropyl]-6-(7-fluoro-1h-pyrazolo[4,3-b]indol-4-yl)-5-methyl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=2C=NNC=2C2=CC(F)=CC=C2N1C1=CC(NC(=O)N2C[C@H](O)CO)=C2N=C1C YGRQDAPOAQBGJC-NSHDSACASA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- TUJVGHCSNXCAFE-UHFFFAOYSA-N 3-bromo-2,6-dimethylpyridine Chemical compound CC1=CC=C(Br)C(C)=N1 TUJVGHCSNXCAFE-UHFFFAOYSA-N 0.000 description 1
- RBXCAMWLXQQRPW-UHFFFAOYSA-N 3-bromo-2-methyl-6-phenylmethoxypyridine Chemical compound C1=C(Br)C(C)=NC(OCC=2C=CC=CC=2)=C1 RBXCAMWLXQQRPW-UHFFFAOYSA-N 0.000 description 1
- AIPWPTPHMIYYOX-UHFFFAOYSA-N 3-bromo-2-methylpyridine Chemical compound CC1=NC=CC=C1Br AIPWPTPHMIYYOX-UHFFFAOYSA-N 0.000 description 1
- UXJVCOJMZKUACU-UHFFFAOYSA-N 3-bromo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine Chemical compound C1CNCC2=C(Br)C=NN21 UXJVCOJMZKUACU-UHFFFAOYSA-N 0.000 description 1
- VWNXCCTWVAQAPL-UHFFFAOYSA-N 3-bromo-6-methoxy-2-methylpyridine Chemical compound COC1=CC=C(Br)C(C)=N1 VWNXCCTWVAQAPL-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- XTFPDGZNWTZCMF-DHZHZOJOSA-N 3-o-methyl 5-o-[(e)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 XTFPDGZNWTZCMF-DHZHZOJOSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GIEQBYJCGYHHSU-UHFFFAOYSA-N 4,7-dichloro-1,10-phenanthroline Chemical compound C1=CC2=C(Cl)C=CN=C2C2=C1C(Cl)=CC=N2 GIEQBYJCGYHHSU-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- UMXRJSSEEXQGHD-UHFFFAOYSA-N 4-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-1-methylpyrazole-3-carboxylic acid Chemical compound OC(=O)C1=NN(C)C=C1N1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 UMXRJSSEEXQGHD-UHFFFAOYSA-N 0.000 description 1
- WXLWYQVBXXHZJE-UHFFFAOYSA-N 4-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-n-(2-hydroxyethyl)benzamide Chemical compound C1=CC(C(=O)NCCO)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 WXLWYQVBXXHZJE-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- JBIXDYBXWDTDLA-UHFFFAOYSA-N 4-bromo-1-ethyl-3,5-dimethylpyrazole Chemical compound CCN1N=C(C)C(Br)=C1C JBIXDYBXWDTDLA-UHFFFAOYSA-N 0.000 description 1
- ZXVFKQRZKKGVNJ-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carbonitrile Chemical compound BrC=1C=NNC=1C#N ZXVFKQRZKKGVNJ-UHFFFAOYSA-N 0.000 description 1
- ONHMWUXYIFULDO-UHFFFAOYSA-N 4-bromo-2-chloropyridine Chemical compound ClC1=CC(Br)=CC=N1 ONHMWUXYIFULDO-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 1
- KYWCWBXGRWWINE-UHFFFAOYSA-N 4-methoxy-N1,N3-bis(3-pyridinylmethyl)benzene-1,3-dicarboxamide Chemical compound COC1=CC=C(C(=O)NCC=2C=NC=CC=2)C=C1C(=O)NCC1=CC=CN=C1 KYWCWBXGRWWINE-UHFFFAOYSA-N 0.000 description 1
- PENVYHXKYYCYML-UHFFFAOYSA-N 4-methoxypyrimidine Chemical compound COC1=CC=NC=N1 PENVYHXKYYCYML-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- YUBBPOBDDZODGU-UHFFFAOYSA-N 5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-4-methylpyridine-2-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 YUBBPOBDDZODGU-UHFFFAOYSA-N 0.000 description 1
- USEIYHVLORQAKA-UHFFFAOYSA-N 5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-6-methyl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(N2C3=CC=C(F)C=C3C=3N(C4OCCCC4)N=CC=32)=C1C USEIYHVLORQAKA-UHFFFAOYSA-N 0.000 description 1
- PPUGETDTHKKFHG-UHFFFAOYSA-N 5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-6-methylpyridine-2-carboxylic acid Chemical compound CC1=NC(C(O)=O)=CC=C1N1C2=CC=C(F)C=C2C2=C1C=NN2C1OCCCC1 PPUGETDTHKKFHG-UHFFFAOYSA-N 0.000 description 1
- WUBOGWOQGQGGGP-UHFFFAOYSA-N 5-bromo-1,4-dimethylindazole Chemical compound CC1=C(Br)C=CC2=C1C=NN2C WUBOGWOQGQGGGP-UHFFFAOYSA-N 0.000 description 1
- TZARUEALSRVVHC-UHFFFAOYSA-N 5-bromo-1-methylpyrazole Chemical compound CN1N=CC=C1Br TZARUEALSRVVHC-UHFFFAOYSA-N 0.000 description 1
- CJUCAYMTGYRYEH-UHFFFAOYSA-N 5-bromo-2,4-dimethylindazole Chemical compound CC1=C(Br)C=CC2=NN(C)C=C12 CJUCAYMTGYRYEH-UHFFFAOYSA-N 0.000 description 1
- YXQQOUJQUKPYGU-UHFFFAOYSA-N 5-bromo-2,6-dimethylindazole Chemical compound C1=C(Br)C(C)=CC2=NN(C)C=C21 YXQQOUJQUKPYGU-UHFFFAOYSA-N 0.000 description 1
- SPILWBCOHGMZCR-UHFFFAOYSA-N 5-bromo-2-(4-fluoropiperidin-1-yl)-4-methylpyrimidine Chemical compound C1=C(Br)C(C)=NC(N2CCC(F)CC2)=N1 SPILWBCOHGMZCR-UHFFFAOYSA-N 0.000 description 1
- YAVKJNIMFGZBSY-UHFFFAOYSA-N 5-bromo-3,4-dimethylpyridin-2-amine Chemical compound CC1=C(C)C(N)=NC=C1Br YAVKJNIMFGZBSY-UHFFFAOYSA-N 0.000 description 1
- QLQQQEUHPBMUCF-UHFFFAOYSA-N 5-bromo-4-methyl-1h-indazole Chemical compound CC1=C(Br)C=CC2=C1C=NN2 QLQQQEUHPBMUCF-UHFFFAOYSA-N 0.000 description 1
- JDNCMHOKWINDKI-UHFFFAOYSA-N 5-bromo-4-methylpyridin-2-amine Chemical compound CC1=CC(N)=NC=C1Br JDNCMHOKWINDKI-UHFFFAOYSA-N 0.000 description 1
- LPQVTZJEIXYDQA-UHFFFAOYSA-N 5-bromo-4-methylpyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1Br LPQVTZJEIXYDQA-UHFFFAOYSA-N 0.000 description 1
- ALRPHTZYJPXPGN-UHFFFAOYSA-N 5-bromo-4-methylpyrimidine Chemical compound CC1=NC=NC=C1Br ALRPHTZYJPXPGN-UHFFFAOYSA-N 0.000 description 1
- UTDBMGRTYFPTEC-UHFFFAOYSA-N 5-bromo-6-methyl-1h-indazole Chemical compound C1=C(Br)C(C)=CC2=C1C=NN2 UTDBMGRTYFPTEC-UHFFFAOYSA-N 0.000 description 1
- UJHCRBDEJPQFIA-UHFFFAOYSA-N 5-bromo-6-methyl-1h-pyridin-2-one Chemical compound CC1=NC(O)=CC=C1Br UJHCRBDEJPQFIA-UHFFFAOYSA-N 0.000 description 1
- SEOZHXRTVJPQPZ-UHFFFAOYSA-N 5-bromo-6-methylpyridin-2-amine Chemical compound CC1=NC(N)=CC=C1Br SEOZHXRTVJPQPZ-UHFFFAOYSA-N 0.000 description 1
- XFHAYQGHHKCVBA-UHFFFAOYSA-N 5-bromo-6-methylpyridine-2,3-diamine Chemical compound CC1=NC(N)=C(N)C=C1Br XFHAYQGHHKCVBA-UHFFFAOYSA-N 0.000 description 1
- DRIWBIDASVEIBC-UHFFFAOYSA-N 5-bromo-n,4-dimethylpyridin-2-amine Chemical compound CNC1=CC(C)=C(Br)C=N1 DRIWBIDASVEIBC-UHFFFAOYSA-N 0.000 description 1
- NNPNVNORGUWKEV-MRVPVSSYSA-N 5-bromo-n-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-4-methylpyrimidin-2-amine Chemical compound C1=C(Br)C(C)=NC(NC[C@H]2OC(C)(C)OC2)=N1 NNPNVNORGUWKEV-MRVPVSSYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- WIZYXBZBDVQMCU-UHFFFAOYSA-N 6-bromo-1,5-dimethylindazole Chemical compound C1=C(Br)C(C)=CC2=C1N(C)N=C2 WIZYXBZBDVQMCU-UHFFFAOYSA-N 0.000 description 1
- IWQKNWIRYSQPQG-UHFFFAOYSA-N 6-bromo-2,5-dimethylindazole Chemical compound C1=C(Br)C(C)=CC2=CN(C)N=C21 IWQKNWIRYSQPQG-UHFFFAOYSA-N 0.000 description 1
- TWYBBHVJHROUNT-UHFFFAOYSA-N 6-bromo-3-(2-hydroxyethyl)-5-methyl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=C(Br)C(C)=NC2=C1NC(=O)N2CCO TWYBBHVJHROUNT-UHFFFAOYSA-N 0.000 description 1
- JLATZTAQRHJLKS-UHFFFAOYSA-N 6-bromo-3-(2-methoxyethyl)-5-methylimidazo[4,5-b]pyridine Chemical compound BrC1=C(C)N=C2N(CCOC)C=NC2=C1 JLATZTAQRHJLKS-UHFFFAOYSA-N 0.000 description 1
- AEPJOXOHJGSRFW-UHFFFAOYSA-N 6-bromo-3-(3-hydroxypropyl)-5-methyl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound C1=C(Br)C(C)=NC2=C1NC(=O)N2CCCO AEPJOXOHJGSRFW-UHFFFAOYSA-N 0.000 description 1
- LRPCETXYROSUAK-SECBINFHSA-N 6-bromo-3-[[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-5-methylimidazo[4,5-b]pyridine Chemical compound C1=NC=2C=C(Br)C(C)=NC=2N1C[C@@H]1COC(C)(C)O1 LRPCETXYROSUAK-SECBINFHSA-N 0.000 description 1
- ZXDKALMAZBWUAP-QMMMGPOBSA-N 6-bromo-3-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-5-methyl-1h-imidazo[4,5-b]pyridin-2-one Chemical compound O=C1NC=2C=C(Br)C(C)=NC=2N1C[C@H]1COC(C)(C)O1 ZXDKALMAZBWUAP-QMMMGPOBSA-N 0.000 description 1
- LRPCETXYROSUAK-VIFPVBQESA-N 6-bromo-3-[[(4s)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl]-5-methylimidazo[4,5-b]pyridine Chemical compound C1=NC=2C=C(Br)C(C)=NC=2N1C[C@H]1COC(C)(C)O1 LRPCETXYROSUAK-VIFPVBQESA-N 0.000 description 1
- YLLZDOJZLKUKEA-UHFFFAOYSA-N 6-bromo-5-methyl-1h-indazole Chemical compound C1=C(Br)C(C)=CC2=C1NN=C2 YLLZDOJZLKUKEA-UHFFFAOYSA-N 0.000 description 1
- LYFZTLWVHLYBEK-UHFFFAOYSA-N 6-bromo-5-methyl-[1,2,4]triazolo[1,5-a]pyridine Chemical compound CC1=C(Br)C=CC2=NC=NN12 LYFZTLWVHLYBEK-UHFFFAOYSA-N 0.000 description 1
- DHIZZMFOQOXHSS-UHFFFAOYSA-N 6-bromo-7-methyl-1,3-dihydroimidazo[4,5-b]pyridin-2-one Chemical compound BrC=1C(=C2C(=NC1)NC(N2)=O)C DHIZZMFOQOXHSS-UHFFFAOYSA-N 0.000 description 1
- XVEGORLAVIFJMX-UHFFFAOYSA-N 6-bromo-7-methyl-1h-imidazo[4,5-b]pyridine Chemical compound CC1=C(Br)C=NC2=C1NC=N2 XVEGORLAVIFJMX-UHFFFAOYSA-N 0.000 description 1
- ACPHVUXUOXRBLZ-UHFFFAOYSA-N 6-chloro-1-(oxan-2-yl)-4H-pyrazolo[4,3-b]indole Chemical compound ClC=1C=CC=2C3=C(NC2C1)C=NN3C3OCCCC3 ACPHVUXUOXRBLZ-UHFFFAOYSA-N 0.000 description 1
- WHMKPEZBIAUHEH-UHFFFAOYSA-N 7-fluoro-1-(oxan-2-yl)-4-pyridin-3-ylpyrazolo[4,3-b]indole Chemical compound C1=2C=NN(C3OCCCC3)C=2C2=CC(F)=CC=C2N1C1=CC=CN=C1 WHMKPEZBIAUHEH-UHFFFAOYSA-N 0.000 description 1
- CVFQHQAWBLVMRP-UHFFFAOYSA-N 7-fluoro-4-(2-methyl-6-phenylmethoxypyridin-3-yl)-1-(oxan-2-yl)pyrazolo[4,3-b]indole Chemical compound C=1C=C(N2C3=CC=C(F)C=C3C=3N(C4OCCCC4)N=CC=32)C(C)=NC=1OCC1=CC=CC=C1 CVFQHQAWBLVMRP-UHFFFAOYSA-N 0.000 description 1
- QMVDOUHMDRBJDO-UHFFFAOYSA-N 7-fluoro-4-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-b]indole 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.Fc1ccc2n(-c3cnn4CCNCc34)c3cn[nH]c3c2c1 QMVDOUHMDRBJDO-UHFFFAOYSA-N 0.000 description 1
- PKVUGSMRGIJJOM-UHFFFAOYSA-N 7-fluoro-4-[2-(4-fluoropiperidin-1-yl)-4-methylpyrimidin-5-yl]-1h-pyrazolo[4,3-b]indole Chemical compound N=1C=C(N2C3=CC=C(F)C=C3C=3NN=CC=32)C(C)=NC=1N1CCC(F)CC1 PKVUGSMRGIJJOM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical compound CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- ALHUCTNQUKJTLS-UHFFFAOYSA-N C1CCC(OC1)n1ncc2[nH]c3ccccc3c12 Chemical compound C1CCC(OC1)n1ncc2[nH]c3ccccc3c12 ALHUCTNQUKJTLS-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000578830 Homo sapiens Methionine aminopeptidase 1 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 1
- 102100028379 Methionine aminopeptidase 1 Human genes 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 229940122344 Peptidase inhibitor Drugs 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- VLAZLCVSFAYIIL-RXMQYKEDSA-N [(2r)-morpholin-2-yl]methanol Chemical compound OC[C@H]1CNCCO1 VLAZLCVSFAYIIL-RXMQYKEDSA-N 0.000 description 1
- VLAZLCVSFAYIIL-YFKPBYRVSA-N [(2s)-morpholin-2-yl]methanol Chemical compound OC[C@@H]1CNCCO1 VLAZLCVSFAYIIL-YFKPBYRVSA-N 0.000 description 1
- BULXYTSDZYPDSB-KEJDIYNNSA-N [(3s)-1-[5-[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]-4-methylpyrimidin-2-yl]pyrrolidin-3-yl]-(3-hydroxyazetidin-1-yl)methanone Chemical compound CC1=NC(N2C[C@H](CC2)C(=O)N2CC(O)C2)=NC=C1N(C1=CC=C(F)C=C1C=12)C=1C=NN2C1CCCCO1 BULXYTSDZYPDSB-KEJDIYNNSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- JLQCIGFLZJRXNY-UHFFFAOYSA-N [4-[[7-fluoro-1-(oxan-2-yl)pyrazolo[4,3-b]indol-4-yl]methyl]phenyl]-morpholin-4-ylmethanone Chemical compound C1=2C=NN(C3OCCCC3)C=2C2=CC(F)=CC=C2N1CC(C=C1)=CC=C1C(=O)N1CCOCC1 JLQCIGFLZJRXNY-UHFFFAOYSA-N 0.000 description 1
- XIKXPJNWHDODFQ-UHFFFAOYSA-N [4-bromo-1-(difluoromethyl)pyrazol-3-yl]methanol Chemical compound OCC1=NN(C(F)F)C=C1Br XIKXPJNWHDODFQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 1
- 238000000668 atmospheric pressure chemical ionisation mass spectrometry Methods 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229950004646 azelnidipine Drugs 0.000 description 1
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 1
- AQUVQGSNKVDBBF-UHFFFAOYSA-N azetidin-3-ylmethanol;hydrochloride Chemical compound Cl.OCC1CNC1 AQUVQGSNKVDBBF-UHFFFAOYSA-N 0.000 description 1
- MJZQSPDYIKSJCN-UHFFFAOYSA-N azetidine-3-carbonitrile;hydrochloride Chemical compound Cl.N#CC1CNC1 MJZQSPDYIKSJCN-UHFFFAOYSA-N 0.000 description 1
- VALZSZJVEFACEZ-UHFFFAOYSA-N azetidine-3-carboxamide Chemical compound NC(=O)C1CNC1 VALZSZJVEFACEZ-UHFFFAOYSA-N 0.000 description 1
- 125000004266 aziridin-1-yl group Chemical group [H]C1([H])N(*)C1([H])[H] 0.000 description 1
- 125000004267 aziridin-2-yl group Chemical group [H]N1C([H])([H])C1([H])* 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229950005341 bucindolol Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- UHKPOGGUWJGGID-UHFFFAOYSA-N carbonic acid;cesium Chemical compound [Cs].OC(O)=O UHKPOGGUWJGGID-UHFFFAOYSA-N 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960003597 clevidipine Drugs 0.000 description 1
- KPBZROQVTHLCDU-GOSISDBHSA-N clevidipine Chemical compound CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@H]1C1=CC=CC(Cl)=C1Cl KPBZROQVTHLCDU-GOSISDBHSA-N 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Natural products C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- YGNHVMNLOAYHEK-UHFFFAOYSA-M copper(1+);toluene;trifluoromethanesulfonate Chemical compound [Cu+].CC1=CC=CC=C1.[O-]S(=O)(=O)C(F)(F)F YGNHVMNLOAYHEK-UHFFFAOYSA-M 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- MEOBNGYEZUNAQF-UHFFFAOYSA-N cyclobutane cyclohexane Chemical compound C1CCC1.C1CCCCC1 MEOBNGYEZUNAQF-UHFFFAOYSA-N 0.000 description 1
- AWWXDZBVBKKKHZ-UHFFFAOYSA-N cyclobutane cyclopentane Chemical compound C1CCC1.C1CCCC1 AWWXDZBVBKKKHZ-UHFFFAOYSA-N 0.000 description 1
- 125000004144 cyclobuten-1-yl group Chemical group [H]C1=C(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical compound C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- JURBTQKVGNFPRJ-UHFFFAOYSA-N ditert-butyl(methyl)phosphane Chemical compound CC(C)(C)P(C)C(C)(C)C JURBTQKVGNFPRJ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical class CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- AZFAPSHASGINRH-UHFFFAOYSA-N ethyl 5-bromo-1-methylpyrazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(Br)N(C)N=1 AZFAPSHASGINRH-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 description 1
- 229950004274 ifetroban Drugs 0.000 description 1
- 229960001195 imidapril Drugs 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007916 intrasternal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960004294 lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- PFKHXPUGZRGBPX-UHFFFAOYSA-N methyl 4-bromo-1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C1=NN(C)C=C1Br PFKHXPUGZRGBPX-UHFFFAOYSA-N 0.000 description 1
- GTZTYNPAPQKIIR-UHFFFAOYSA-N methyl 4-bromo-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(Br)C(C)=C1 GTZTYNPAPQKIIR-UHFFFAOYSA-N 0.000 description 1
- IZHGDXUQVBDEBG-UHFFFAOYSA-N methyl 5-bromo-6-methylpyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(Br)C(C)=N1 IZHGDXUQVBDEBG-UHFFFAOYSA-N 0.000 description 1
- LNTAAMVZKGYIIA-UHFFFAOYSA-N methyl 6-amino-5-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(N)C(Br)=C1 LNTAAMVZKGYIIA-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical group O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229960001006 picotamide Drugs 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229950004891 pranidipine Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- QHJLLDJTVQAFAN-UHFFFAOYSA-M sodium meclofenamate monohydrate Chemical compound O.[Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl QHJLLDJTVQAFAN-UHFFFAOYSA-M 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KCFFETCHURQXPV-UHFFFAOYSA-N tert-butyl 1,2-dihydropyridine-3-carboxylate Chemical compound C(C)(C)(C)OC(=O)C=1CNC=CC1 KCFFETCHURQXPV-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- IGNTWNVBGLNYDV-UHFFFAOYSA-N triisopropylphosphine Chemical compound CC(C)P(C(C)C)C(C)C IGNTWNVBGLNYDV-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698369P | 2012-09-07 | 2012-09-07 | |
| US61/698,369 | 2012-09-07 | ||
| PCT/US2013/058527 WO2014039831A1 (en) | 2012-09-07 | 2013-09-06 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015527399A true JP2015527399A (ja) | 2015-09-17 |
| JP2015527399A5 JP2015527399A5 (enExample) | 2016-11-04 |
Family
ID=49170939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531237A Abandoned JP2015527399A (ja) | 2012-09-07 | 2013-09-06 | 置換−１，４−ジヒドロピラゾロ［４，３−ｂ］インドール |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9475816B2 (enExample) |
| EP (1) | EP2909212B1 (enExample) |
| JP (1) | JP2015527399A (enExample) |
| WO (1) | WO2014039831A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022543460A (ja) * | 2019-08-06 | 2022-10-12 | ドメイン・セラピューティクス | 神経ペプチドｆｆ受容体アンタゴニストとしての５－ヘテロアリール－ピリジン－２－アミン化合物 |
| JP2023524863A (ja) * | 2020-05-08 | 2023-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式のヘテロ環 |
| JP2023552485A (ja) * | 2020-12-14 | 2023-12-15 | キノシス・セラピューティクス・ピーティーワイ・リミテッド | オキシトシン受容体モジュレーター |
| JP2024516860A (ja) * | 2021-05-05 | 2024-04-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| US20170042806A1 (en) | 2015-04-29 | 2017-02-16 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| CA3086668A1 (en) * | 2018-02-05 | 2019-08-08 | Universite De Strasbourg | Compounds and compositions for the treatment of pain |
| CN113372281A (zh) * | 2020-03-09 | 2021-09-10 | 河北中科金辉药业有限公司 | 一种特硝唑的合成方法 |
| WO2021224291A1 (en) * | 2020-05-08 | 2021-11-11 | Merck Patent Gmbh | Tricyclic heterocycles useful as tead binders |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| ES2102195T3 (es) | 1992-12-28 | 1997-07-16 | Eisai Co Ltd | Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides. |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| ATE355279T1 (de) | 1998-08-07 | 2006-03-15 | Novartis Vaccines & Diagnostic | Pyrazole als modulatoren des östrogenrezeptors |
| US6462036B1 (en) | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| WO2000027822A2 (en) | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| US6297238B1 (en) | 1999-04-06 | 2001-10-02 | Basf Aktiengesellschaft | Therapeutic agents |
| WO2002042293A1 (en) | 2000-11-21 | 2002-05-30 | Smithkline Beecham P.L.C. | Isoquinoline derivatives useful in the treatment of cns disorders |
| GB0111186D0 (en) | 2001-05-08 | 2001-06-27 | Smithkline Beecham Plc | Novel compounds |
| AU2003234567A1 (en) | 2002-05-15 | 2003-12-02 | Janssen Pharmaceutica N.V. | N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors |
| MXPA05009576A (es) * | 2003-03-07 | 2005-12-12 | Abbott Lab | Inhibidores de pirazol-quinasa triciclicos y tetraciclicos, fundidos. |
| CA2560691A1 (en) * | 2004-03-24 | 2005-10-13 | Abbott Laboratories | Tricyclic pyrazole kinase inhibitors |
| US7816536B2 (en) | 2005-06-10 | 2010-10-19 | The Research Foundation Of State University Of New York | 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same |
| US20080027052A1 (en) | 2006-07-10 | 2008-01-31 | Sharon Moe | Methods for treating cystic kidney disease |
| CN100586932C (zh) | 2007-01-26 | 2010-02-03 | 中国医学科学院医药生物技术研究所 | 抗肿瘤化合物及其制备方法 |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
-
2013
- 2013-09-06 WO PCT/US2013/058527 patent/WO2014039831A1/en not_active Ceased
- 2013-09-06 JP JP2015531237A patent/JP2015527399A/ja not_active Abandoned
- 2013-09-06 US US14/426,369 patent/US9475816B2/en not_active Expired - Fee Related
- 2013-09-06 EP EP13762702.2A patent/EP2909212B1/en active Active
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022543460A (ja) * | 2019-08-06 | 2022-10-12 | ドメイン・セラピューティクス | 神経ペプチドｆｆ受容体アンタゴニストとしての５－ヘテロアリール－ピリジン－２－アミン化合物 |
| JP2023524863A (ja) * | 2020-05-08 | 2023-06-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式のヘテロ環 |
| JP2023552485A (ja) * | 2020-12-14 | 2023-12-15 | キノシス・セラピューティクス・ピーティーワイ・リミテッド | オキシトシン受容体モジュレーター |
| JP2024516860A (ja) * | 2021-05-05 | 2024-04-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体 |
| JP7843780B2 (ja) | 2021-05-05 | 2026-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置に使用するための２，８－ジヒドロピラゾロ［３，４－ｂ］インドール誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014039831A1 (en) | 2014-03-13 |
| EP2909212B1 (en) | 2017-02-22 |
| US20150225405A1 (en) | 2015-08-13 |
| US9475816B2 (en) | 2016-10-25 |
| EP2909212A1 (en) | 2015-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2909212B1 (en) | Substituted 1,4-dihydropyrazolo[4,3-b]indoles | |
| KR102924294B1 (ko) | 아졸-융합된 피리다진-3(2h)-온 유도체 | |
| US9434743B2 (en) | Indazole derivatives | |
| US20230295171A1 (en) | Fused heteroaromatic pyrrolidinones | |
| US9663514B2 (en) | Substituted 6-aza-isoindolin-1-one derivatives | |
| HUE032720T2 (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| US20200061041A1 (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| KR20220015492A (ko) | Ｊａｋ１ 저해제로서의 피페리딘４일 아제티딘 유도체 | |
| US20250340563A1 (en) | Fused pyridazine derivatives as nlrp3 inhibitors | |
| JP2025179155A (ja) | Ｓｓｔｒ４アゴニストとしてのｎ－ヘテロアリールアルキル－２－（ヘテロシクリル及びヘテロシクリルメチル）アセトアミド誘導体 | |
| US12428403B2 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | |
| JP2018500329A (ja) | フマギロール誘導体 | |
| EA053259B1 (ru) | Конденсированные с азолом производные пиридазин-3(2н)-она | |
| TW201433567A (zh) | 吲唑衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160901 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160914 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20170325 |